Optimi Health Corp. News Releases

Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering

Mon, 16 Mar 2026 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - March 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today announced that it has commenced an underwritten public offering in the United States (the "Offering") of its common shares, no par value (the "Shares"), pursuant to a registration statement filed with the United States...

Optimi Health berichtet über den frühen klinischen Einsatz natürlicher Psilocybin-Kapseln zur Behandlung therapieresistenter Depressionen in Australien

Thu, 26 Feb 2026 07:00:00 -0500

Erste Patienten im Jahr 2026 außerhalb sponsorengeleiteter klinischer Studien im Rahmen des regulierten australischen Zugangsmodells behandelt Vancouver, British Columbia--(Newsfile Corp. - Donnerstag, 26. Februar 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" oder das "Unternehmen"), ein von Health Canada lizenzierter Hersteller pharmazeutischer Psychedelika-Produkte in pharmazeutischer Qualität, gab heute bekannt, dass in Australien nun Patienten mit...

Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia

Thu, 26 Feb 2026 07:00:00 -0500

First Patients of 2026 Treated Outside of Sponsor-Led Clinical Trials Under Australia's Regulated Framework Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today reported that patients diagnosed with treatment-resistant depression (TRD) have now been treated in Australia using the Company's naturally...

Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression

Thu, 19 Feb 2026 02:00:00 -0500

Naturally-Derived 5 mg Psilocybin Capsules Mark the Company's Second Drug in Market Under Australia's Authorised Prescriber Scheme Vancouver, British Columbia--(Newsfile Corp. - February 19, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today announced the export of its GMP-manufactured natural 5 mg psilocybin capsules to Australia for the treatment of...

Optimi Health schließt Psilocybin-Export nach Australien zur Behandlung therapieresistenter Depression ab

Thu, 19 Feb 2026 02:00:00 -0500

Natürlich gewonnene 5-mg-Psilocybin-Kapseln markieren das zweite Arzneimittel des Unternehmens auf dem australischen Markt im Rahmen des Authorised Prescriber Scheme Vancouver, British Columbia--(Newsfile Corp. - Donnerstag, 19. Februar 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" oder das "Unternehmen"), ein von Health Canada lizenzierter Hersteller von psychedelischen Arzneimitteln in pharmazeutischer Qualität, gab heute den Export seiner nach GMP-Standards...

Optimi Health Reports First MDMA-Assisted Treatments of 2026 are Underway Across an Expanded Network of Australian Clinics

Tue, 17 Feb 2026 07:00:00 -0500

MDMA-assisted therapy for PTSD delivered through Optimi's direct-to-clinic supply model under Australia's Authorised Prescriber Scheme Vancouver, British Columbia--(Newsfile Corp. - February 17, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that the first patients of 2026 have been treated using the Company's MDMA capsules at authorised clinics across...

Optimi Health meldet Beginn der ersten MDMA-gestützten Behandlungen im Jahr 2026 in einem erweiterten Netzwerk australischer Kliniken

Mon, 16 Feb 2026 01:00:00 -0500

MDMA-gestützte Therapie bei PTBS wird über Optimis Direktbelieferungsmodell für Kliniken im Rahmen des australischen Authorised Prescriber Scheme bereitgestellt Vancouver, British Columbia--(Newsfile Corp. - Montag, 16. Februar 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" oder das "Unternehmen"), ein von Health Canada lizenzierter Hersteller pharmazeutischer psychedelischer Arzneimittelprodukte, gab heute bekannt, dass die ersten Patientinnen und Patienten des...

Optimi Health Completes MDMA Export for PTSD Treatment Under Australia's Authorised Prescriber Scheme

Mon, 09 Feb 2026 07:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that it has completed its first export of MDMA capsules to Australia in 2026 under the Authorised Prescriber Scheme.The export included 1,000 of Optimi's MDMA capsules in a standardised 60 mg dosage form, supplied for use in authorised clinical...

Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules

Mon, 26 Jan 2026 07:00:00 -0500

Australia's Department of Health has issued import permits for Optimi's MDMA and psilocybin capsules for use under the Authorised Prescriber Scheme Vancouver, British Columbia--(Newsfile Corp. - January 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that it has completed a production cycle for its MDMA and psilocybin capsules intended for supply...

Optimi Health Announces Equity Incentive Grants and Corporate Update

Fri, 16 Jan 2026 07:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, today announced a series of equity compensation and marketing initiatives designed to support its growth strategy and enhance market awareness.Equity Incentive GrantsOptimi announces that, pursuant to its equity incentive plan and subject to acceptance by the Canadian Securities...